Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice

INTRODUCTION: The treatment of choice for Atypical Hemolytic Uremic Syndrome (aHUS) is the monoclonal antibody eculizumab. The objective of this study was to assess the efficacy and safety of eculizumab in a cohort of kidney transplant patients suffering from aHUS. METHODS: Description of the prospe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: de Andrade, Luis Gustavo Modelli, Contti, Mariana Moraes, Nga, Hong Si, Bravin, Ariane Moyses, Takase, Henrique Mochida, Viero, Rosa Marlene, da Silva, Trycia Nunes, Chagas, Kelem De Nardi, Palma, Lilian Monteiro Pereira
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685617/
https://ncbi.nlm.nih.gov/pubmed/29136640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0188155
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller